Alphavac System News Today

AngioDynamics received CE Mark approval for its AlphaVac F18 system, which treats pulmonary embolism and removes thrombi and emboli.

Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market ...

Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused

AngioDynamics this week announced it received FDA 510(k) clearance for its AlphaVac F18 system to treat pulmonary embolism (PE).

New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical Scenarios ...

FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens treatment options. Sales slightly below consensus, but pro forma basis sees growth.

122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-up ...

AngioDynamics, Inc. , a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the...

The medical devices company is taking an exciting approach to treating some of the most complex diseases.

The medical devices company is taking an exciting approach to treating some of the most complex diseases.